KPTI - Karyopharm Q4 topline shines expects XPOVIO sales growth

Karyopharm Therapeutics (KPTI) Q4 results:Revenues: $35.1M (+93.9%); Xpovio Sales: $20M; License and other revenue: $14.8M.Net loss: ($43.4M) (-11%); loss/share: ($0.59) (-22%).2021 Financial Outlook: non-GAAP R&D and SG&A expenses to be in the range of $280M to $300M.Q1 Outlook: Expects XPOVIO sales to return to growth beginning in the first quarter of 2021.Cash, cash equivalents, restricted cash and investments as of December 31, 2020 totaled $276.7M, compared to $265.8M as of December 31, 2019.Karyopharm expects that its existing cash, cash equivalents and investments, and the revenue it expects to generate from XPOVIO product sales, as well as revenue generated from its license agreements, will be sufficient to fund its planned operations into late 2022.The company said that the clinical development of XPOVIO in solid tumor indications continues to advance, with top-line data from the Phase 3 SIENDO study in endometrial cancer expected in the second half of 2021.Karyopharm shares up ~3% premarket.Previously (Feb. 11): Karyopharm Therapeutics

For further details see:

Karyopharm Q4 topline shines, expects XPOVIO sales growth